Abstract
In Rwanda, the prevalence of viral hepatitis (HCV) is poorly understood. The current study investigated the prevalence and risk factors of HCV infection in Rwanda. A total of 324 patients attending Rwanda Military Hospital were randomly selected and a questionnaire was administered to determine the risk factors. Blood was collected and screened for anti-HCV antibodies and seropositive samples were subjected to polymerase chain reaction method. Hematology abnormalities in the HCV infected patients were also investigated. Anti-HCV antibody and active HCV infection were found in 16.0% and 9.6% of total participants, respectively. Prevalence was highest (28.4%; 19/67) among participants above 55 years and least (2.4%; 3/123) among younger participants (18–35 years). There was a significant (P = 0.031) relationship between place of residence and HCV infection with residents of Southern Province having significantly higher prevalence. The hematological abnormalities observed in the HCV infected patients included leukopenia (48.4%; 15/52), neutropenia (6.5%; 2/52), and thrombocytopenia (25.8%; 8/52). The HCV infection was significantly higher in the older population (>55 years) and exposure to injection from traditional practitioners was identified as a significant (P = 0.036) risk factor of infection. Further studies to determine the factors causing the high prevalence of HCV in Rwanda are recommended.
Highlights
About 130–150 million people are living with chronic HCV infection [1] with about 350,000–500,000 lives lost every year [2, 3]
The infection progresses into chronic infections and gradually develops liver fibrosis which leads to cirrhosis, liver damage, and hepatocellular carcinoma (HCC) [6]
The current study shows a high prevalence of HCV infection in Rwanda
Summary
About 130–150 million people are living with chronic HCV infection [1] with about 350,000–500,000 lives lost every year [2, 3]. A prevalence of 4.9% was estimated in a 2011 study [11] but a recent review by Karoney and Siiki indicates that this figure could be an underestimation [12]. This is because of challenges such as barriers to screening, cost-related factors, and inadequate knowledge and awareness of hepatitis C [13]
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have